Patents by Inventor Brett Skolnick

Brett Skolnick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sphingosine 1 phosphate receptor agonists for neuroprotection
    Patent number: 11207301
    Abstract: Methods of treating conditions for which S1P-mediated neuroprotection is medically indicated, comprising administering to a subject in need thereof an agonist of the sphingosine 1-phosphate receptor (S1P receptor); such as a compound having the following structure (See Formula 1): or a pharmaceutically acceptable salt, stereoisomer, homolog, hydrate or solvate thereof.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: December 28, 2021
    Assignee: RECEPTOS LLC
    Inventors: Kristen R. Taylor Meadows, Brett Skolnick, Deepak Dalvie
  • SPHINGOSINE 1 PHOSPHATE RECEPTOR AGONISTS FOR NEUROPROTECTION
    Publication number: 20200085795
    Abstract: Methods of treating conditions for which S1P-mediated neuroprotection is medically indicated, comprising administering to a subject in need thereof an agonist of the sphingosine 1-phosphate receptor (S1P receptor); such as a compound having the following structure (See Formula 1): or a pharmaceutically acceptable salt, stereoisomer, homolog, hydrate or solvate thereof.
    Type: Application
    Filed: May 8, 2018
    Publication date: March 19, 2020
    Inventors: Kristen R. Taylor Meadows, Brett Skolnick, Deepak Dalvie
  • Use of factor VIIa or factor VIIa equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage (ICH) in a selected subpopulation of ICH patients
    Patent number: 8354377
    Abstract: The invention relates to a method for preventing or attenuating one or more complications of intracerebral haemorrhage (ICH), the method comprising: (i) selecting an ICH patient who exhibits one or more of the following characteristics: age?70, baseline ICH volume?60 mL, baseline IVH volume?5 mL, and elapsed time since onset of symptoms of less than about 2.5 hours; and (ii) administering to said patient in need thereof an effective amount of a first coagulation agent comprising Factor VIIa or a Factor VIIa equivalent.
    Type: Grant
    Filed: January 16, 2009
    Date of Patent: January 15, 2013
    Assignee: Novo Nordisk Health Care AG
    Inventors: Brett Skolnick, Nikolai Constantin Brun, Kamilla Begtrup
  • USE OF FACTOR VIIA OR FACTOR VIIA EQUIVALENTS FOR PREVENTING OR ATTENUATING HAEMORRHAGE GROWTH, AND/OR OEDEMA GENERATION FOLLOWING INTRACEREBRAL HAEMORRHAGE (ICH) IN A SELECTED SUBPOPULATION OF ICH PATIENTS
    Publication number: 20110014179
    Abstract: The invention relates to a method for preventing or attenuating one or more complications of intracerebral haemorrhage (ICH), the method comprising: (i) selecting an ICH patient who exhibits one or more of the following characteristics: age?70, baseline ICH volume?60 mL, baseline IVH volume?5 mL, and elapsed time since onset of symptoms of less than about 2.5 hours; and (ii) administering to said patient in need thereof an effective amount of a first coagulation agent comprising Factor VIIa or a Factor VIIa equivalent.
    Type: Application
    Filed: January 16, 2009
    Publication date: January 20, 2011
    Applicant: Novo Nordisk HealthCare A/G
    Inventors: Brett Skolnick, Nikolai Constantin Brun, Kamilla Begtrup
  • Use of factor VIIa or factor VIIa equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage
    Publication number: 20070243183
    Abstract: The invention relates to the use of Factor VIIa or a Factor VIIa equivalent for the manufacture of a medicament for preventing complications in ICH patients.
    Type: Application
    Filed: March 27, 2007
    Publication date: October 18, 2007
    Applicant: Novo Nordisk A/S
    Inventors: Nikolai Brun, Elisabeth Erhardtsen, Brett Skolnick
  • Uses of factor VIIa or factor VIIa equivalents for treating late complications of trauma
    Publication number: 20070078086
    Abstract: The invention relates to the use of Factor VIIa or a Factor VIIa equivalent for the manufacture of a medicament for preventing late complications in trauma patients.
    Type: Application
    Filed: August 1, 2006
    Publication date: April 5, 2007
    Applicant: Novo Nordisk HealthCare A/G
    Inventors: Mads Axelsen, Elisabeth Erhardtsen, Brett Skolnick
  • Use of factor VIIa or factor VIIa equivalents for treating trauma
    Publication number: 20070078087
    Abstract: The invention relates to the use of Factor VIIa or a Factor VIIa equivalent for the manufacture of a medicament for treatment of trauma.
    Type: Application
    Filed: August 2, 2006
    Publication date: April 5, 2007
    Applicant: Novo Nordisk HealthCare A/G
    Inventors: Mads Axelsen, Elisabeth Erhardtsen, Brett Skolnick
  • Use of factor VIIa or factor VIIa equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage
    Publication number: 20060019894
    Abstract: The invention relates to the use of Factor VIIa or a Factor VIIa equivalent for the manufacture of a medicament for preventing complications in ICH patients.
    Type: Application
    Filed: June 29, 2005
    Publication date: January 26, 2006
    Applicant: Novo Nordisk A/S
    Inventors: Nikolai Brun, Elisabeth Erhardtsen, Brett Skolnick